ASCO Annual Meeting: Lung Cancer

In this interview we discuss the requirements for the effective implementation of a lung cancer screening program.

From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.

This slide show highlights some of the top studies and news on lung cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

The addition of the anti-EGFR antibody necitumumab to gemcitabine-cisplatin chemotherapy resulted in a modest but significant benefit to patients with stage IV squamous cell non-small-cell lung cancer, according to results of the SQUIRE study presented at ASCO.

The addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to a new phase II study.

Thoracic radiotherapy along with prophylactic cranial irradiation (PCI) significantly prolonged progression-free and overall survival in patients with extensive-stage small-cell lung cancer, according to results of a new study presented at ASCO.

The addition of the MET-targeting antibody onartuzumab to erlotinib added no benefit, and may have been detrimental, to patients with MET-amplified stage IIIb/IV metastatic non–small-cell lung cancer, according to a new phase III trial.

As part of our coverage of the 2014 ASCO Annual Meeting, we discuss chemotherapy's curative role in treating lung cancer.

Implementation of a national lung cancer screening program using low-dose CT will identify almost 55,000 additional lung cancer cases over 5 years, but will add $9.3 billion to Medicare expenditures.

A novel agent known as AZD9291 showed promising results in a phase I dose escalation trial among non-small-cell lung cancer (NSCLC) patients whose disease progresses after treatment with EGFR-targeting tyrosine kinase inhibitors.